Health Care

"Insect 2151" Challenges Teens to Reimagine the Future Through Insect-Inspired Innovation, Offering $180,000 in Scholarships and Inspiring the Next Generation of InnovatorsATLANTA, June 16,...

MUNICH, June 16, 2026 /PRNewswire/ -- Innovative Molecules GmbH ("IM"), a clinical-stage biopharmaceutical company focused on herpesvirus-mediated diseases, today announced the advancement of its virology...

AMSTERDAM, 16 juin 2026 (GLOBE NEWSWIRE) -- Le professeur Ahmad AbuSalah, titulaire d’un doctorat, directeur du Digital Innovation Hub au King Faisal Specialist Hospital & Research Centre (KFSH), présente le modèle de l’hôpital visant à créer un écosystème d’intelligence artificielle appliquée en radiologie lors du congrès HLTH Europe 2026, qui se tiendra du 15 au 18 juin à Amsterdam. Il met en avant la manière dont l’IA peut passer d’un besoin clinique à un impact mesurable grâce à une gouvernance responsable, à l’intégration des flux de travail et à une adoption centrée sur l’humain.

SkinVision Pro connects AI-powered skin health assessments directly to medical practices, giving doctors structured information before the consultation begins. AMSTERDAM, June 16, 2026 /PRNewswire/...

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.

MORGANTOWN, W.Va., June 15, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, Haider Jaffrey, DDS is acknowledged as a Pinnacle Lifetime Member for his...

DERM Zero is a world-first - using Class III regulated medical device1 technology to deliver autonomous clinical grade skin cancer assessments from a standard...

ARLINGTON, Va., June 15, 2026 /PRNewswire/ -- The National Alliance on Mental Illness (NAMI), the nation's leading grassroots mental health organization, today announced its...

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI

Veteran healthcare leader, Bret Lyman, adds third territory as Utah's senior population continues to growWEST JORDAN, Utah, June 15, 2026 /PRNewswire/ -- Registered nurse and...